R. Salpini

Domenico Di Carlo, C. Perno, M. Andreoni, 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

High Burden of HBV-Infection and Atypical HBV Strains among HIV-infected Cameroonians.

M. Andreoni, V. Colizzi, C. Perno, 2016, Current HIV research.

Targeting SARS-CoV-2 nsp13 Helicase and Assessment of Druggability Pockets: Identification of Two Potent Inhibitors by a Multi-Site In Silico Drug Repurposing Approach

F. Ceccherini‐Silberstein, E. Tramontano, S. Alcaro, 2022, Molecules.

Reliable timescale inference of HBV genotype A origin and phylodynamics.

M. Ciccozzi, E. Tanzi, M. Giovanetti, 2015, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.

Characterization of drug-resistance mutations in HBV D-genotype chronically infected patients, naïve to antiviral drugs.

C. Perno, C. Perno, A. Bertoli, 2011, Antiviral research.

Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression

Y. Louzoun, M. Andreoni, C. Perno, 2015, Hepatology.

Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses

F. Ceccherini‐Silberstein, Y. Assaraf, S. Alcaro, 2020, Drug Resistance Updates.

Detecting Hepatitis B Viral Amino Acid Sequence Mutations in Occult Hepatitis B Infections via Bayesian Partition Model

Yang Liu, Valentina Svicher, C. Perno, 2013 .

Role of hepatitis B virus genetic barrier in drug-resistance and immune-escape development.

F. Ceccherini‐Silberstein, H. Fleury, F. Mazzotta, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.

F. Ceccherini‐Silberstein, C. Perno, A. Spanò, 2009, Journal of hepatology.

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro

F. Ceccherini‐Silberstein, C. Delaugerre, M. Levrero, 2020, Viruses.

Hepatitis B reactivation characterized by HBsAg negativity and anti-HbsAg antibodies persistence in haematopoietic stem cell transplanted patient after lamivudine withdrawal

V. Svicher, G. Maffongelli, L. Sarmati, 2017, BMC Infectious Diseases.

Lamivudine-resistance mutations can be selected even at very low levels of hepatitis B viraemia.

F. Ceccherini‐Silberstein, A. Ursitti, C. Perno, 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors

Stefano Alcaro, Anna Artese, Lucia Parrotta, 2012, PloS one.

Overlapping structure of hepatitis B virus (HBV) genome and immune selection pressure are critical forces modulating HBV evolution.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2013, The Journal of general virology.

Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B

C. Perno, A. Nuccitelli, V. Svicher, 2020, Gut.

Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro

Domenico Di Carlo, F. Ceccherini‐Silberstein, H. Fleury, 2017, Oncotarget.

Quantification of intrahepatic total HBV DNA in liver biopsies of HBV-infected patients by a modified version of COBAS® Ampliprep/COBAS®TaqMan HBV test v2.0

M. Ciotti, F. Stazi, C. Perno, 2017, Medical Microbiology and Immunology.

Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection.

B. Berkhout, H. Fleury, M. Andreoni, 2015, The Journal of infection.

Snapshot on drug‐resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

C. Perno, M. Andreoni, M. Angelico, 2013, Journal of medical virology.

An Increase in the Levels of Middle Surface Antigen Characterizes Patients Developing HBV-Driven Liver Cancer Despite Prolonged Virological Suppression

F. Ceccherini‐Silberstein, Y. Oda, C. Perno, 2021, Microorganisms.

Molecular epidemiology of HIV type 1 CRF02_AG in Cameroon and African patients living in Italy.

Nazle M. Veras, Rebecca R. Gray, A. Tatem, 2011, AIDS research and human retroviruses.

High rates of chronic HBV genotype E infection in a group of migrants in Italy from West Africa: Virological characteristics associated with poor immune clearance

M. Andreoni, C. Perno, V. Svicher, 2018, PloS one.

Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection.

Valentina Svicher, Jens Verheyen, Valeria Micheli, 2012, Antiviral research.

The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitro.

F. Ceccherini‐Silberstein, H. Fleury, M. Levrero, 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Molecular analysis of hepatitis B virus in Bulgaria

M. Ciccozzi, M. Ciotti, A. Lo Presti, 2013, Journal of medical virology.

Key mutations in the C-terminus of the HBV surface glycoprotein correlate with lower HBsAg levels in vivo, hinder HBsAg secretion in vitro and reduce HBsAg structural stability in the setting of HBeAg-negative chronic HBV genotype-D infection

Domenico Di Carlo, S. Grelli, M. Andreoni, 2020, Emerging microbes & infections.

Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

L. Milanesi, F. Ceccherini‐Silberstein, E. Teti, 2021, Viruses.

HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets

F. Ceccherini‐Silberstein, H. Fleury, M. Andreoni, 2018, Viruses.

HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort

E. Teti, M. Andreoni, L. Coppola, 2021, Microorganisms.

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort

E. Teti, M. Andreoni, S. Parisi, 2023, Viruses.

HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy

E. Teti, M. Andreoni, V. Svicher, 2019, Scientific Reports.

A recent epidemiological cluster of acute hepatitis B genotype F1b infection in a restricted geographical area of Italy.

C. Perno, R. Mariani, M. Dalessandro, 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

HBsAg genetic elements critical for immune escape correlates with HBV reactivation upon immunosuppression

Y. Louzoun, C. Perno, M. Andreoni, 2014 .

Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance

C. Perno, M. Andreoni, A. Bertoli, 2011, Infection.

Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon

V. Colizzi, P. Ndumbe, C. Perno, 2011, The Pediatric infectious disease journal.

Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers

E. Teti, M. Andreoni, G. Sotgiu, 2021, Scientific Reports.

Characterization of drug resistance mutations in naïve and ART‐treated patients infected with HIV‐1 in Yaounde, Cameroon

M. Andreoni, V. Colizzi, J. Torimiro, 2012, Journal of medical virology.

Different Patterns of HIV-1 Replication in MACROPHAGES is Led by Co-Receptor Usage

F. Ceccherini‐Silberstein, S. Aquaro, C. Perno, 2019, Medicina.

Key genetic elements, single and in clusters, underlying geographically dependent SARS-CoV-2 genetic adaptation and their impact on binding affinity for drugs and immune control

F. Ceccherini‐Silberstein, S. Alcaro, G. Costa, 2020, The Journal of antimicrobial chemotherapy.

Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile

F. Ceccherini‐Silberstein, S. Alcaro, G. Costa, 2022, Microbiology spectrum.

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.

F. Ceccherini‐Silberstein, P. Narciso, A. Antinori, 2012, AIDS research and human retroviruses.

HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: evidence from routine clinical practice in Cameroon

F. Ceccherini‐Silberstein, V. Colizzi, C. Fokunang, 2019, BMC Infectious Diseases.

HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Cross-sectional Design.

F. Ceccherini‐Silberstein, V. Colizzi, J. Eberle, 2016, Current HIV research.

SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021

R. Shafer, F. Ceccherini‐Silberstein, S. Alcaro, 2021, Microbiology spectrum.

Characterisation of HIV-1 molecular transmission clusters among newly diagnosed individuals infected with non-B subtypes in Italy

F. Ceccherini‐Silberstein, O. Turriziani, A. Antinori, 2019, Sexually Transmitted Infections.

New insights into hepatitis B virus lymphotropism: Implications for HBV-related lymphomagenesis

V. Svicher, L. Sarmati, V. Malagnino, 2023, Frontiers in Oncology.

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients

F. Ceccherini‐Silberstein, E. Teti, M. Andreoni, 2022, Biomedicines.

HIV-2 A-subtype gp125C2-V3-C3 mutations and their association with CCR5 and CXCR4 tropism

F. Ceccherini‐Silberstein, C. Perno, V. Svicher, 2011, Archives of Virology.

HIV-1 Drug Susceptibility to Potential Second- and Third-Line Antiretroviral Regimens among Cameroonian Patients: Evidence from a Crosssectional Design

F. Ceccherini‐Silberstein, V. Colizzi, J. Eberle, 2017 .

Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an In Silico Drug Repurposing Approach

F. Ceccherini‐Silberstein, E. Tramontano, S. Alcaro, 2023, J. Chem. Inf. Model..

SARS-CoV-2 Mutations and Variants May Muddle the Sensitivity of COVID-19 Diagnostic Assays

F. Ceccherini‐Silberstein, V. Svicher, L. Carioti, 2022, Microorganisms.

Identification of gp120 polymorphisms in HIV-1 B subtype potentially associated with resistance to fostemsavir.

F. Ceccherini‐Silberstein, S. Aquaro, C. Perno, 2020, The Journal of antimicrobial chemotherapy.

Drug Resistance Among Drug-naive and First-line Antiretroviral Treatment-failing Children in Cameroon

V. Colizzi, P. Ndumbe, C. Perno, 2011, The Pediatric Infectious Disease Journal.

GS-17-The integration of Hepatitis B virus into human genome is a common event in the setting of HBeAg negative disease: Implications for the treatment and management of CHB

C. Perno, A. Nuccitelli, V. Svicher, 2019, Journal of Hepatology.

Determinants of worse liver‐related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort

C. Mussini, A. Tavelli, S. Lo Caputo, 2023, Liver international : official journal of the International Association for the Study of the Liver.

Molecular and Structural Aspects of Clinically Relevant Mutations of SARS-CoV-2 RNA-Dependent RNA Polymerase in Remdesivir-Treated Patients

F. Ceccherini‐Silberstein, Federica Moraca, B. Catalanotti, 2023, Pharmaceuticals.